Deletion of histone deacetylase 3 reveals critical roles in S phase progression and DNA damage control

被引:323
作者
Bhaskara, Srividya [1 ]
Chyla, Brenda J. [1 ]
Amann, Joseph M. [1 ,2 ,3 ]
Knutson, Sarah K. [1 ]
Cortez, David [1 ,4 ]
Sun, Zu-Wen [1 ,4 ]
Hiebert, Scott W. [1 ,4 ]
机构
[1] Vanderbilt Univ, Sch Med, Dept Biochem, Nashville, TN 37232 USA
[2] Vanderbilt Univ, Sch Med, Dept Med, Nashville, TN 37232 USA
[3] Vanderbilt Univ, Sch Med, Dept Canc Biol, Nashville, TN 37232 USA
[4] Vanderbilt Univ, Sch Med, Vanderbilt Ingram Canc Ctr, Nashville, TN 37232 USA
关键词
D O I
10.1016/j.molcel.2008.02.030
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Histone deacetylases (HDACs) are enzymes that modify key residues in histones to regulate chromatin architecture, and they play a vital role in cell survival, cell-cycle progression, and tumorigenesis. To understand the function of Hdac3(-/-), a critical component of the N-CoR/SMRT repression complex, a conditional allele of Hdac3 was engineered. Cre-recombinasemediated inactivation of Hdac3 led to a delay in cell-cycle progression, cell-cycle-dependent DNA damage, and apoptosis in mouse embryonic fibroblasts (MEFs). While no overt defects in mitosis were observed in Hdac3(-/-) MEFs, including normal H3Ser10 phosphorylation, DNA damage was observed in Hdac3(-/-) interphase cells, which appears to be associated with defective DNA double-strand break repair. Moreover, we noted that Hdac3(-/-) MEFs were protected from DNA damage when quiescent, which may provide a mechanistic basis for the action of HDAC inhibitors on cycling tumor cells.
引用
收藏
页码:61 / 72
页数:12
相关论文
共 58 条
[1]   Acute myeloid leukemia: Therapeutic impact of epigenetic drugs [J].
Altucci, L ;
Clarke, N ;
Nebbioso, A ;
Scognamiglio, A ;
Gronemeyer, H .
INTERNATIONAL JOURNAL OF BIOCHEMISTRY & CELL BIOLOGY, 2005, 37 (09) :1752-1762
[2]   ETO, a target of t(8;21) in acute leukemia, makes distinct contacts with multiple histone deacetylases and binds mSin3A through its oligomerization domain [J].
Amann, JM ;
Nip, J ;
Strom, DK ;
Lutterbach, B ;
Harada, H ;
Lenny, N ;
Downing, JR ;
Meyers, S ;
Hiebert, SW .
MOLECULAR AND CELLULAR BIOLOGY, 2001, 21 (19) :6470-6483
[3]   Checking on DNA damage in S phase [J].
Bartek, J ;
Lukas, C ;
Lukas, J .
NATURE REVIEWS MOLECULAR CELL BIOLOGY, 2004, 5 (10) :792-804
[4]   Nuclear levels and patterns of histone H3 modification and HP1 proteins after inhibition of histone deacetylases [J].
Bártová, E ;
Pacherník, J ;
Harnicarová, A ;
Kovarík, A ;
Kovaríková, M ;
Hofmanová, J ;
Skalníková, M ;
Kozubek, M ;
Kozubek, S .
JOURNAL OF CELL SCIENCE, 2005, 118 (21) :5035-5046
[5]   Modifications of H3 and H4 during chromatin replication, nucleosome assembly, and histone exchange [J].
Benson, LJ ;
Gu, YL ;
Yakovleva, T ;
Tong, K ;
Barrows, C ;
Strack, CL ;
Cook, RG ;
Mizzen, CA ;
Annunziato, AT .
JOURNAL OF BIOLOGICAL CHEMISTRY, 2006, 281 (14) :9287-9296
[6]   Genomewide studies of histone deacetylase function in yeast [J].
Bernstein, BE ;
Tong, JK ;
Schreiber, SL .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2000, 97 (25) :13708-13713
[7]   Anticancer activities of histone deacetylase inhibitors [J].
Bolden, Jessica E. ;
Peart, Melissa J. ;
Johnstone, Ricky W. .
NATURE REVIEWS DRUG DISCOVERY, 2006, 5 (09) :769-784
[8]   Functional uncoupling of MCM helicase and DNA polymerase activities activates the ATR-dependent checkpoint [J].
Byun, TS ;
Pacek, M ;
Yee, MC ;
Walter, JC ;
Cimprich, KA .
GENES & DEVELOPMENT, 2005, 19 (09) :1040-1052
[9]   Inhibition of histone deacetylation: A strategy for tumor radiosensitization [J].
Camphausen, Kevin ;
Tofilon, Philip J. .
JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (26) :4051-4056
[10]   Histone deacetylases 5 and 9 govern responsiveness of the heart to a subset of stress signals and play redundant roles in heart development [J].
Chang, SR ;
McKinsey, TA ;
Zhang, CL ;
Richardson, JA ;
Hill, JA ;
Olson, EN .
MOLECULAR AND CELLULAR BIOLOGY, 2004, 24 (19) :8467-8476